Atherosclerosis is associated with plasminogen activator inhibitor type-1 in chronic haemodialysis patients

Youming Peng1, Hong Liu, Fuyou Liu

  • 1Division of Nephrology, Nephrology Institute of Central South University, Changasha, Hunan, China.

Insights

Circulating levels and arterial wall expression of plasminogen activator inhibitor-1 (PAI-1) are associated with atherosclerosis in hemodialysis patients. PAI-1 may predict atherothrombosis risk and serve as a target for anti-inflammatory therapies.

Area of Science:

  • Nephrology and Vascular Biology
  • Biomarkers of Atherosclerosis
  • Inflammation and Thrombosis

Background:

  • Chronic kidney disease patients on hemodialysis (HD) exhibit accelerated atherosclerosis.
  • Plasminogen activator inhibitor-1 (PAI-1) plays a role in thrombosis and inflammation.
  • The association of PAI-1 levels and expression with atherosclerosis in HD patients requires further investigation.

Purpose of the Study:

  • To investigate the association between circulating PAI-1 levels and PAI-1 expression in internal iliac artery walls with atherosclerotic disease.
  • To assess the predictive value of PAI-1 for carotid atherosclerosis in non-diabetic HD patients.

Main Methods:

  • Sixty-eight non-diabetic HD patients and 50 healthy controls were studied.
  • Atherosclerosis was assessed using carotid intima-media thickness (IMT) and plaque score via ultrasound.
  • Serum PAI-1, CRP, IL-6, and lipid profiles were measured; PAI-1 expression in internal iliac arteries was quantified immunohistochemically.

Main Results:

  • HD patients showed significantly increased carotid IMT and plaque prevalence compared to controls.
  • Circulating PAI-1 levels and internal iliac artery PAI-1 expression were significantly correlated with carotid IMT and plaque score.
  • Multivariate analysis identified serum PAI-1 concentration and PAI-1 expression as independent predictors of carotid atherosclerosis.

Conclusions:

  • Circulating PAI-1 and its vascular expression are associated with markers of inflammation (CRP, IL-6) and dyslipidemia.
  • PAI-1 levels and expression are independent predictors of carotid atherosclerosis in HD patients.
  • PAI-1 may indicate a chronic activated endothelium, identify atherothrombosis risk, and be a target for anti-inflammatory therapies.
Abstract

Related Concept Videos

Atherosclerosis I: Introduction01:30

Atherosclerosis I: Introduction

Atherosclerosis is a progressive disorder characterized by the buildup of plaques on the arterial inner wall, causing them to narrow and harden over time. These plaques comprise lipids, calcium, blood components, carbohydrates, and fibrous tissue. The process primarily affects the intima of large and medium-sized arteries, reducing blood flow in any artery.Etiology and risk factorsThe cause of atherosclerosis is multifactorial, involving a complex interplay among endothelial injury, lipid...
Peripheral Artery Disease I: Introduction01:30

Peripheral Artery Disease I: Introduction

Peripheral artery disease (PAD) predominantly results from atherosclerosis, which involves the accumulation of fatty deposits, or plaques, within the walls of arteries. This causes them to narrow and harden, significantly reducing blood flow. PAD predominantly affects the legs, particularly the arteries supplying the thighs and calves. In rare cases, it may involve other arteries, including those in the arms.Etiology of PAD:The principal cause of PAD is atherosclerosis, which results from fatty...
Anticoagulant Drugs: Low-Molecular-Weight Heparins01:30

Anticoagulant Drugs: Low-Molecular-Weight Heparins

Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
Hemodialysis I: Introduction01:25

Hemodialysis I: Introduction

Hemodialysis (HD) is a medical treatment that artificially removes waste products, excess fluids, and toxins from the blood when the kidneys are no longer able to perform these functions effectively. In this process, blood is filtered through a semipermeable membrane, allowing for the selective removal of waste while preserving necessary components like blood cells and proteins. Hemodialysis is typically performed in patients with end-stage renal disease (ESRD) or severe kidney...
Atherosclerosis II: Clinical Manifestations and Diagnostic Tests01:27

Atherosclerosis II: Clinical Manifestations and Diagnostic Tests

Atherosclerosis is a progressive disorder that leads to the thickening and narrowing of arterial walls due to plaque buildup. This condition can cause various symptoms depending on the arteries affected:Coronary Artery Disease (CAD): This condition affects the coronary arteries and may lead to chest pain (angina), shortness of breath (dyspnea), heart attacks, and other heart disease symptoms.Cerebrovascular Disease: This affects blood flow to the brain, causing transient ischemic attacks (TIAs)...
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...